Zai Lab (ZLAB) Stock Forecast & Price Target

Compare

708 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZLAB Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Zai

Lab

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZLAB Stock 12 Month Forecast

Average Price Target

$36.13

▲(96.68% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Zai Lab in the last 3 months. The average price target is $36.13 with a high forecast of $47.00 and a low forecast of $21.80. The average price target represents a 96.68% change from the last price of $18.37.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","48":"$48","23.25":"$23.3","31.5":"$31.5","39.75":"$39.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,23.25,31.5,39.75,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.42,20.61846153846154,22.81692307692308,25.01538461538462,27.213846153846156,29.412307692307692,31.610769230769233,33.80923076923077,36.00769230769231,38.206153846153846,40.40461538461538,42.60307692307693,44.80153846153846,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.42,19.782307692307693,21.144615384615385,22.50692307692308,23.86923076923077,25.231538461538463,26.593846153846158,27.95615384615385,29.31846153846154,30.680769230769233,32.043076923076924,33.40538461538462,34.767692307692315,{"y":36.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.42,18.680000000000003,18.94,19.200000000000003,19.46,19.720000000000002,19.98,20.240000000000002,20.5,20.76,21.02,21.28,21.54,{"y":21.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.82,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 55, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.13,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$47.00

Average Price Target$36.13

Lowest Price Target$21.80

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yigal Nochomovitz

Citi

$47

Buy

155.85%

Upside

Reiterated

03/09/26

Zai Lab: Validated Povetacicept Data and China IgAN Opportunity Support Upside and Buy RatingWe are encouraged by pove’s demonstrated strong efficacy/safety profile, though we await China-specific data from VRTX. In the meantime, we caution against over-analyzing the APAC subgroup data given no breakdown by ZLAB-specific geographies, relatively low N, and incomplete information on baseline characteristics-by-region. While ZLAB mgmt. has not yet disclosed the number of China patients in the study, they pointed to ~10-20% as ZLAB’s typical enrollment share and do not see any biological reason to expect Chinese patients would respond differently to pove, so the data may support possible accelerated approval in China too. We continue to see pove as a near-term driver of the stock amidst the business’ ongoing transformation and increased focus on the pipeline (more here).

David Li

Bank of America Securities

$19.5→$21.8

Hold

18.67%

Upside

Reiterated

02/27/26

Bank of America Securities Sticks to Their Hold Rating for Zai Lab (ZLAB)

Li Watsek

Cantor Fitzgerald

$55→$37

Buy

101.42%

Upside

Reiterated

02/26/26

Cantor Fitzgerald Reaffirms Their Buy Rating on Zai Lab (ZLAB)

Anupam Rama

J.P. Morgan

$39

Buy

112.30%

Upside

Reiterated

02/05/26

J.P. Morgan Reaffirms Their Buy Rating on Zai Lab (ZLAB)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$42.91→$36.99

Buy

101.36%

Upside

Reiterated

01/15/26

Zai Lab (ZLAB) Receives a Buy from Goldman Sachs

Michael Yee

UBS

$35

Buy

90.53%

Upside

Initiated

01/07/26

Zai Lab initiated with a Buy at UBSZai Lab initiated with a Buy at UBS

Jonathan Chang

Leerink Partners

$74

Buy

302.83%

Upside

Reiterated

10/21/25

Leerink Partners Sticks to Their Buy Rating for Zai Lab (ZLAB)

Jack Lin

Morgan Stanley

$52→$48

Buy

161.30%

Upside

Reiterated

09/21/25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Zai Lab (NASDAQ: ZLAB)

Kelly Shi

Jefferies

$52

Buy

183.07%

Upside

Initiated

08/24/25

Jefferies assumes Zai Lab (ZLAB) at BuyJefferies analyst Kelly Shi assumes coverage on Zai Lab (NASDAQ: ZLAB) with a Buy rating and a price target of $52.00.

Louise Chen

Scotiabank

$55

Buy

199.40%

Upside

Reiterated

07/02/25

Scotiabank Keeps Their Buy Rating on Zai Lab (ZLAB)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yigal Nochomovitz

Citi

$47

Buy

155.85%

Upside

Reiterated

03/09/26

David Li

Bank of America Securities

$19.5→$21.8

Hold

18.67%

Upside

Reiterated

02/27/26

Bank of America Securities Sticks to Their Hold Rating for Zai Lab (ZLAB)

Li Watsek

Cantor Fitzgerald

$55→$37

Buy

101.42%

Upside

Reiterated

02/26/26

Cantor Fitzgerald Reaffirms Their Buy Rating on Zai Lab (ZLAB)

Anupam Rama

J.P. Morgan

$39

Buy

112.30%

Upside

Reiterated

02/05/26

J.P. Morgan Reaffirms Their Buy Rating on Zai Lab (ZLAB)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$42.91→$36.99

Buy

101.36%

Upside

Reiterated

01/15/26

Zai Lab (ZLAB) Receives a Buy from Goldman Sachs

Michael Yee

UBS

$35

Buy

90.53%

Upside

Initiated

01/07/26

Zai Lab initiated with a Buy at UBSZai Lab initiated with a Buy at UBS

Jonathan Chang

Leerink Partners

$74

Buy

302.83%

Upside

Reiterated

10/21/25

Leerink Partners Sticks to Their Buy Rating for Zai Lab (ZLAB)

Jack Lin

Morgan Stanley

$52→$48

Buy

161.30%

Upside

Reiterated

09/21/25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Zai Lab (NASDAQ: ZLAB)

Kelly Shi

Jefferies

$52

Buy

183.07%

Upside

Initiated

08/24/25

Jefferies assumes Zai Lab (ZLAB) at BuyJefferies analyst Kelly Shi assumes coverage on Zai Lab (NASDAQ: ZLAB) with a Buy rating and a price target of $52.00.

Louise Chen

Scotiabank

$55

Buy

199.40%

Upside

Reiterated

07/02/25

Scotiabank Keeps Their Buy Rating on Zai Lab (ZLAB)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zai Lab

3 Months

xxx

Success Rate

6/13 ratings generated profit

Average Return

-1.58%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of -1.58% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

7/13 ratings generated profit

Average Return

+4.35%

reiterated a buy rating last month

Copying Anupam Rama's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +4.35% per trade.

2 Years

xxx

Success Rate

4/13 ratings generated profit

Average Return

-20.58%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of -20.58% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZLAB Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZLAB has received 8 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. ZLAB average Analyst price target in the past 3 months is 36.13.

Each month's total comprises the sum of three months' worth of ratings.

ZLAB Financial Forecast

ZLAB Earnings Forecast

Next quarter’s earnings estimate for ZLAB is -$0.47 with a range of -$0.51 to -$0.41. The previous quarter’s EPS was -$0.46. ZLAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ZLAB has Performed in-line its overall industry.

ZLAB Sales Forecast

Next quarter’s sales forecast for ZLAB is $117.97M with a range of $111.07M to $131.50M. The previous quarter’s sales results were $128.15M. ZLAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ZLAB has Performed in-line its overall industry.

ZLAB Stock Forecast FAQ

What is ZLAB’s average 12-month price target, according to analysts?

Based on analyst ratings, Zai Lab’s 12-month average price target is 36.13.

What is ZLAB’s upside potential, based on the analysts’ average price target?

Zai Lab has 96.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZLAB a Buy, Sell or Hold?

Zai Lab has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Zai Lab’s price target?

The average price target for Zai Lab is 36.13. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $47.00 ,the lowest forecast is $21.80. The average price target represents 96.68% Increase from the current price of $18.37.

What do analysts say about Zai Lab?

Zai Lab’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of ZLAB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Zai Lab (ZLAB) Stock Forecast & Price Target

ZLAB Analyst Ratings

ZLAB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zai Lab

ZLAB Analyst Recommendation Trends

ZLAB Financial Forecast

ZLAB Earnings Forecast

ZLAB Sales Forecast

ZLAB Stock Forecast FAQ

Detailed List of Analyst Forecasts